Institute for Clinical Research Official Portal

Clinical Research Centre

Hospital Pulau Pinang
Georgetown, Pulau Pinang

WhoWe Are

Established in 2001 and operational since 2003, Clinical Research Centre Hospital Pulau Pinang (CRC HPP) began in a small office with four staff members at the current CTC clinic, relocated to the 1st floor of the ACC Building in 2009, and expanded to the CRC Complex building in 2019 to enhance support for research activities at Hospital Pulau Pinang. The mission of CRC HPP is to improve patient health outcomes through ethical and high-quality clinical research, while its vision is to synthesize evidence within the Malaysian context to inform and update policies. The objectives of CRC HPP are to conduct and support research by providing essential services and facilities, promote a research culture and enhance research capacity through data resources and training, and produce impactful, evidence-based research to advance the healthcare system.

OurTeam

NAME POSITION QUALIFICATION EMAIL
Dr. Yoon Chee Kin Head, Acute Medicine Physician MBBChBAO, MMed, MRCP, MRCP (IRE) dryoonck@moh.gov.my 
Ng Ru Shing Deputy Head, Pharmacist MPharm nrshing@moh.gov.my 
Dr. Wee Hong Chin Medical Officer MD wee.hongchin@moh.gov.my 
Teo Ley Khim Pharmacist (Admin Manager I) MPharm teolk@crc.moh.gov.my 
Ch'ng Chin Chin Pharmacist (Admin Manager II) BPharm, MPH chngchinchin@moh.gov.my 
Lim Yen Li Pharmacist MPharm limyenli@crc.moh.gov.my 
Dr. Sivasangari a/p Subramaniam Research Officer
PhD sivasangarisubramaniam@moh.gov.my  
Dr. Kelvin Beh Khai Meng Medical Officer BM kelvinbeh@crc.moh.gov.my 
Dr. Goh Lay Hoon Medical Officer MD gohlayhoon@moh.gov.my 
Dr. Tan Xue Fang Medical Officer MBBS tanxuefang@moh.gov.my 
Dr. Cheng Jie Ling Medical Officer MBBS chengjl@moh.gov.my 
Zarina bt Che Umar Sister Diploma In Nursing zarinacu@gmail.com 
Khadijah bt Majid Administrative Assistant Bachelor Degree khadijah.abdmajid@moh.gov.my  

 

InvestigatorsHighlight

Image

 

Head of CRC, Acute Medicine Physician, Hospital Pulau Pinang

Email: dryoonck@moh.gov.my 

MBBChBAO (IRE), MRCP (UK), MRCP (IRE), MMed (S’PORE), MBA

Areas of interest: Non-communicable diseases, Maternal health, Diabetes

Awards and achievements:

  • Excellent Service Award, Ministry of Health Malaysia (2007, 2012, 2017, 2022)
  • Clinical Research Malaysia Award for Top Ministry of Health Study Site - 2022

Dr. Yoon is dedicated to translating the extensive body of research evidence into tangible improvements in community health. His work involves not only applying this knowledge to enhance health outcomes but also shaping the future of clinical practice through the development of guidelines. In addition, Dr. Yoon actively contributes to special interest groups that focus on critical areas such as non-communicable diseases, maternal health, and diabetes. His commitment extends to influencing policy and practice in these fields, aiming to bridge the gap between research and real-world health applications.

Research Highlights

Dr. Yoon has contributed as an author to Clinical Practice Guidelines (CPG) on topics including bronchial asthma in adults, advanced care planning, and urinary tract infections during pregnancy. Additionally, he serves as a reviewer for the Malaysian Clinical Practice Guidelines (CPG) concerning systemic lupus erythematosus, hepatitis B, and rheumatoid arthritis.

Project Highlights

Image
Image
Image
Image
  MyGenom initiative: Establishing a reference genome for precision medicine in Malaysia
  Ministry of Health (MOH) Biobank, Institute for Medical Research, Ministry of Health
NMRR-23-01702-MJA Incidence and Characteristics of Acute Kidney Injury among Hospitalized Dengue Patients
NMRR-23-02619-POU A prospective cohort study on a novel surgical technique Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal diseases in Malaysia.
NMRR-23-02480-SGV Prevelance Risk Factor and Etiology of onychomycosis in psoriasis patients
NMRR-22-02846-I21 Development and Validation of Usability and Satisfaction of Health Application Questionnaire (USHA)
NMRR-18-2593-43921 Epidemiology, incidence, and clinical outcomes of snake bites treated in Hospital Pulau Pinang
RSCH-23-00281-MGB Incidence and Characteristics of Acute Kidney Injury among Hospitalized off pump and on pump CABG patients
NMRR  id - 2024study done in 2024
NMRR-20-2951-57003 A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer (TIGIT)
NMRR-22-02070-23D A Randomized, Double-blind, Four-Arm Active and Placebo-controlled Dose-Finding Trial to Evaluate the Efficacy, Tolerability, Safety, and Dose Response Of LYT-100 in Patients with Idiopathic Pulmonary Fibrosis (IPF)
NMRR-23-01871-OBV A Randomized, Double-Blind, Parallel Group, Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthmas (LITHOS)
NMRR-23-00606-M4P MASTER PROTOCOL: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer
NMRR-24-00102-YRK A Randomised, Placebo-Controlled, Double-Blind, Multi-Centre, 4-week, 3-way Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared with BGF Delivered by MDI HFA in Participants with Chronic Obstructive Pulmonary Disease
NMRR-24-01815-KDL Studies of Heart & Kidney Protection with BI 690517 in combination with empagliflozin: A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease
NMRR-23-01854-V44 A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed Treatment With Osimertinib (SAFFRON)

List of Publications associated with CRC HPP

Services at CRC Hospital Pulau Pinang

CRC HPP provides training through workshops and consultations:

  • Statistical consultation
  • Protocol development
  • Research design
  • Project management
  • Randomization
  • Sample size calculation
  • NMRR registration 

Clinical Trial Unit

Meeting Room

CTU Equipments

Laboratory

Monitoring Room

CRC Clinic

Seminar Room

Drug Storage Room

Meet Our Collaborators

Client 1
Client 1
Client 1
Client 1
Client 1
Client 1
Client 1

Upcoming Activities

Client 1

Highlighted Activities

Good Clinical Practice

  • 24th April – 26th April 2024

Enrichment & engagement Visit to CTU Hosp Ampang

  • 10th May 2023

Northern Research Camp 

  • 12th June -14th June 2024

BIOBANK training

  • 24th July 2023

Liason Officer Training Workshop

  • 12th July 2024

Enrichment & engagement visit to CRC HUS

  • 19th Sept 2023

ICR & DR Aaron Neal (NIH, USA) visit to CRC HPP

  • 8th Sept 2022

NPRA audit

  • 25th Sept -27th Sept 2023

CRC Hospital Pulau Pinang

Clinical Research Centre Complex,
Hospital Pulau Pinang,
Jalan Residensi,
Georgetown,
10450 Pulau Pinang
 

Main Phone: +604-2225580/5578

 

ICR
National Institutes of Health (NIH)
Ministry of Health Malaysia
Institute For Clinical Research
Block B4, National Institutes of Health (NIH)
No.1, Jalan Setia Murni U13/52, Seksyen U13
40170 Shah Alam, Selangor Darul Ehsan
Malaysia
 
Phone: 603-3362 7700
Email: contact@crc.gov.my
 

NIH Official Portal

Client 1

Follow us on